Advertisement

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy

  • Eric GuedjEmail author
  • Thomas Graillon
  • Olivier Chinot
  • David Taieb
Letter to the Editor
  • 360 Downloads

Sir,

With a worldwide incidence of 45,000 cases, meningioma is the most common nonglial primary intracranial tumour. Although the tumour is often associated with indolent behaviour, in many patients it shows aggressive features and is associated with poor outcomes. After complete resection, the 5-year recurrence rates for grade I (benign), grade II (atypical) and grade III (anaplastic) tumours have been estimated to be 5%, 40% and 80%, respectively [1, 2]. Very few treatment options are available at this stage. The progression-free survival (PFS) in patients with aggressive recurrent meningiomas is less than 30% at 6 months, while the median overall survival is 3 years in patients with grade III tumour [3]. It is therefore of major importance to develop new treatment options.

In recent years, peptide receptor radionuclide therapy (PRRT) with somatostatin analogues (SSAs) has become increasingly important in the treatment of patients with tumours expressing somatostatin receptor (SST),...

Notes

Funding

This work was conducted in the framework of DHU-Imaging thanks to the support of the A*MIDEX project (no. ANR-11-IDEX-0001-02) (Investissements d’Avenir French Government programme, managed by the French National Research Agency, ANR).

Compliance with ethical standards

Conflicts of interest

None.

Ethical approval

This article does not describe any studies with human participants performed by any of the authors.

References

  1. 1.
    Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma-report of the RANO/PET group. Neuro Oncol. 2017;19:1576–87.  https://doi.org/10.1093/neuonc/nox112.CrossRefGoogle Scholar
  2. 2.
    Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–91.  https://doi.org/10.1016/S1470-2045(16)30321-7.CrossRefGoogle Scholar
  3. 3.
    Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16:829–40.  https://doi.org/10.1093/neuonc/not330.CrossRefGoogle Scholar
  4. 4.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.  https://doi.org/10.1056/NEJMoa1607427.CrossRefGoogle Scholar
  5. 5.
    Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2017;127:660–9.  https://doi.org/10.3171/2016.8.JNS16995.CrossRefGoogle Scholar
  6. 6.
    Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo M, et al. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014;9:e111624.  https://doi.org/10.1371/journal.pone.0111624.CrossRefGoogle Scholar
  7. 7.
    Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18:1021–7.  https://doi.org/10.1093/neuonc/now001.CrossRefGoogle Scholar
  8. 8.
    Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med. 2015;56:1748–51.  https://doi.org/10.2967/jnumed.115.155853.CrossRefGoogle Scholar
  9. 9.
    Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171–6.  https://doi.org/10.2967/jnumed.114.147256.CrossRefGoogle Scholar
  10. 10.
    Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407–16.  https://doi.org/10.1007/s00259-009-1115-z.CrossRefGoogle Scholar
  11. 11.
    Sabet A, Ahmadzadehfar H, Herrlinger U, Wilinek W, Biersack HJ, Ezziddin S. Successful radiopeptide targeting of metastatic anaplastic meningioma: case report. Radiat Oncol. 2011;6:94.  https://doi.org/10.1186/1748-717X-6-94.CrossRefGoogle Scholar
  12. 12.
    Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol. 2016;18:1538–47.  https://doi.org/10.1093/neuonc/now060.CrossRefGoogle Scholar
  13. 13.
    van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–606.Google Scholar
  14. 14.
    Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99.  https://doi.org/10.1186/1748-717X-7-99.CrossRefGoogle Scholar
  15. 15.
    Backhaus P, Huss S, Kösek V, Weckesser M, Rahbar K. Lung metastases of intracranial atypical meningioma diagnosed on post therapeutic imaging after 177Lu-DOTATATE therapy. Clin Nucl Med. 2018;43:e184–5.  https://doi.org/10.1097/RLU.0000000000002077.Google Scholar
  16. 16.
    Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41.  https://doi.org/10.1007/s00259-018-4044-x.CrossRefGoogle Scholar
  17. 17.
    Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.  https://doi.org/10.2967/jnumed.112.107524.CrossRefGoogle Scholar
  18. 18.
    Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9.  https://doi.org/10.1007/s00259-017-3678-4.CrossRefGoogle Scholar
  19. 19.
    Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490–500.  https://doi.org/10.1007/s00259-017-3688-2.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Service de Médecine Nucléaire, CHU Timone, Assistance Publique-Hôpitaux de MarseilleMarseilleFrance
  2. 2.CNRS, Ecole Centrale Marseille, UMR 7249, Institut FresnelAix-Marseille UniversitéMarseilleFrance
  3. 3.CERIMEDAix-Marseille UniversitéMarseilleFrance
  4. 4.Service de Neurochirurgie, CHU Timone, Assistance Publique-Hôpitaux de MarseilleMarseilleFrance
  5. 5.CNRS, UMR7286, CRN2MAix-Marseille UniversitéMarseilleFrance
  6. 6.Service de Neuro-Oncologie, CHU Timone, Assistance Publique-Hôpitaux de MarseilleMarseilleFrance
  7. 7.Inserm, U1068-CNRS 7258, Cancer Research Center of MarseilleAix-Marseille UniversitéMarseilleFrance

Personalised recommendations